These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6456937)

  • 1. Proteolysis of factor B by plasma kallikrein and plasmin.
    Ikari N; Niinobe M; Fujii S
    FEBS Lett; 1981 Aug; 131(1):143-6. PubMed ID: 6456937
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen.
    Miles LA; Greengard JS; Griffin JH
    Thromb Res; 1983 Feb; 29(4):407-17. PubMed ID: 6344314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of factor B of the complement system by kallikrein and its light chain.
    Hiemstra PS; Daha MR; Bouma BN
    Thromb Res; 1985 Jun; 38(5):491-503. PubMed ID: 3848216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.
    Ichinose A; Fujikawa K; Suyama T
    J Biol Chem; 1986 Mar; 261(8):3486-9. PubMed ID: 3081506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural changes accompanying enzymatic activation of human Hageman factor.
    Revak SD; Cochrane CG; Johnston AR; Hugli TE
    J Clin Invest; 1974 Sep; 54(3):619-27. PubMed ID: 4277669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High molecular weight kininogen: its inability to correct the clotting of kininogen-deficient plasma after cleavage of bradykinin by plasma kallikrein, plasmin or trypsin.
    Chan JY; Movat HZ; Burrowes CE
    Thromb Res; 1979; 14(6):817-24. PubMed ID: 157559
    [No Abstract]   [Full Text] [Related]  

  • 7. Naloxone attenuates the hypotension induced by Hageman factor.
    Goldstein DJ; Pitterman AB; Frech M; Kelly G; Pisano JJ; Keiser HR
    Life Sci; 1982 Jul; 31(4):341-5. PubMed ID: 6815399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of purified plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system.
    Laake K; Osterud B
    Thromb Res; 1974 Dec; 5(6):759-72. PubMed ID: 4280635
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma kallikrein-mediated activation of the renin-angiotensin system does not require prior acidification of prorenin.
    Derkx FH; Schalekamp MP; Bouma B; Kluft C; Schalekamp MA
    J Clin Endocrinol Metab; 1982 Feb; 54(2):343-8. PubMed ID: 6459340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of guinea-pig plasma prekallikrein. Activation by prekallikrein activator derived from guinea-pig skin.
    Yamamoto T; Kozono K; Okamoto T; Kato H; Kambara T
    Biochim Biophys Acta; 1980 Aug; 614(2):511-25. PubMed ID: 6967737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinins released from horse heat-acid-denaturated plasma by plasmin, plasma kallikrein, trypsin and Bothrops kininogenase.
    Gapanhuk E; Henriques OB
    Biochem Pharmacol; 1970 Jun; 19(6):2091-6. PubMed ID: 4254789
    [No Abstract]   [Full Text] [Related]  

  • 13. Origin of the high molecular weight activator of prekallikrein.
    Bagdasarian A; Lahiri B; Colman RW
    J Biol Chem; 1973 Nov; 248(22):7742-7. PubMed ID: 4127217
    [No Abstract]   [Full Text] [Related]  

  • 14. Bovine prekallikrein activator with functional activity as Hageman factor.
    Komiya M; Nagasawa S; Suzuki T
    J Biochem; 1972 Nov; 72(5):1205-18. PubMed ID: 4675207
    [No Abstract]   [Full Text] [Related]  

  • 15. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.
    Kaplan AP; Kay AB; Austen KF
    J Exp Med; 1972 Jan; 135(1):81-97. PubMed ID: 5009705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of Hageman factor (factor XII) of the guinea pig to prekallikrein activator and inhibition of the formed kallikrein by a natural plasma inhibitor.
    Takeuchi Y; Movat HZ
    Eur J Immunol; 1972 Aug; 2(4):345-9. PubMed ID: 4538864
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion of bovine prekallikrein to kallikrein. Evidence of limited proteolysis of prekallikrein by bovine Hageman factor (factor XII).
    Takahashi H; Nagasawa S; Suzuki T
    FEBS Lett; 1972 Jul; 24(1):98-100. PubMed ID: 5086625
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of iodipamide on human C3 and factor B in vitro.
    Durda PJ; Pagano RJ; Bauman N; Brockman JA
    J Allergy Clin Immunol; 1982 Nov; 70(5):353-60. PubMed ID: 6922882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of trypsin, beta-factor XIIa, and plasma kallikrein with a trypsin inhibitor isolated from barley seeds: a comparison with the corn inhibitor of activated Hageman factor.
    Chong GL; Reeck GR
    Thromb Res; 1987 Oct; 48(2):211-21. PubMed ID: 3501175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of beta-XIIa (Hageman factor fragment) from human plasma.
    Tankersley DL; Alving BM; Finlayson JS
    Thromb Res; 1982 Feb; 25(4):307-17. PubMed ID: 6978550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.